zurück Home | NSABP - R04 |
|||||||||||||
Fragestellung |
Welche Chemotherapie ist bei der praeoperativen Radiochemotherapie des Rektumkarzinoms am besten? Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04 Michael J. O’Connell, J Clin Oncol 32:1927-1934. © 2014 Patients with clinical stage II or III rectal cancer who were undergoing preoperative RT (45 Gy in 25 fractions over 5 weeks plus a boost of 5.4 Gy to 10.8 Gy in three to six daily fractions) were randomly assigned to one of the following chemotherapy regimens: continuous intravenous infusional fluorouracil (CVI FU; 225 mg/m 2 , 5 days per week), with or without intravenous oxaliplatin (50 mg/m 2 once per week for 5 weeks) or oral capecitabine (825 mg/m 2 twice per day, 5 days per week), with or without oxaliplatin (50 mg/m 2 once per week for 5 weeks). Before random assignment, the surgeon indicated whether the patient was eligible for sphincter-sparing surgery based on clinical staging. The surgical end points were complete pathologic response (pCR), sphincter-sparing surgery, and surgical downstaging (conversion to sphincter-sparing surgery). Results From September 2004 to August 2010, 1,608 patients were randomly assigned. No significant differences in the rates of pCR, sphincter-sparing surgery, or surgical downstaging were identified between the CVI FU and capecitabine regimens or between the two regimens with or without oxaliplatin. Patients treated with oxaliplatin experienced significantly more grade 3 or 4 diarrhea (P .001). Conclusion Administering capecitabine with preoperative RT achieved similar rates of pCR, sphincter-sparing surgery, and surgical downstaging compared with CVI FU. Adding oxaliplatin did not improve surgical outcomes but added significant toxicity. The definitive analysis of local tumor control, disease-free survival, and overall survival will be performed when the protocol-specified number of events has occurred. Ann Surg. 2014 Mar 25. [Epub ahead of print] Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer: Patient-Reported Outcomes in National Surgical Adjuvant Breast and Bowel Project Randomized Trial R-04. Russell MM1, Ganz PA, Lopa S, Yothers G, Ko CY, Arora A, Atkins JN, Bahary N, Soori GS, Robertson JM, Eakle J, Marchello BT, Wozniak TF, Beart RW Jr, Wolmark N. Author information Abstract OBJECTIVE:: National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04 was a randomized controlled trial of neoadjuvant chemoradiotherapy in patients with resectable stage II-III rectal cancer. We hypothesized that patients who underwent abdominoperineal resection (APR) would have a poorer quality of life than those who underwent sphincter-sparing surgery (SSS). METHODS:: To obtain patient-reported outcomes (PROs) we administered two symptom scales at baseline and 1 year postoperatively: the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and the European Organization for the Research and Treatment of Cancer module for patients with Colorectal Cancer Quality of Life Questionnaire (EORTC QLQ-CR38). Scoring was stratified by nonrandomly assigned definitive surgery (APR vs SSS). Analyses controlled for baseline scores and stratification factors: age, gender, stage, intended surgery, and randomly assigned chemoradiotherapy. RESULTS:: Of 1,608 randomly assigned patients, 987 had data for planned analyses; 62% underwent SSS; 38% underwent APR. FACT-C total and subscale scores were not statistically different by surgery at 1 year. For the EORTC QLQ-CR38 functional scales, APR patients reported worse body image (70.3 vs 77.0, P = 0.0005) at 1 year than did SSS patients. Males undergoing APR reported worse sexual enjoyment (43.7 vs 54.7, P = 0.02) at 1 year than did those undergoing SSS. For the EORTC QLQ-CR38 symptom scale scores, APR patients reported worse micturition symptoms than the SSS group at 1 year (26.9 vs 21.5, P = 0.03). SSS patients reported worse gastrointestinal tract symptoms than did the APR patients (18.9 vs 15.2, P < 0.0001), as well as weight loss (10.1 vs 6.0, P = 0.002). CONCLUSIONS:: Symptoms and functional problems were detected at 1 year by EORTC QLQ-CR38, reflecting different symptom profiles in patients who underwent APR than those who underwent SSS. Information from these PROs may be useful in counseling patients anticipating surgery for rectal cancer. | |||||||||||||
Ergebnis |
|
|||||||||||||
- | RCh - OP | OP - RCh | p | |||||||||||
5a-DFS | ||||||||||||||
OS | ||||||||||||||
pathologisch komplette Remission | - | - | ||||||||||||
Random |
| |||||||||||||
5-FU | kontinuierliche Infusion | 225mg/qm in 24h | 5 Tage/Woche | 5 Wochen | ||||||||||
Oxaliplatin | ELOXATIN® | 50mg/qm | 1x/Woche | 5 Wochen | ||||||||||
Capecitabine | XELODA® | 825 mg/qm oral 2x/Tag | 5 Tage/Woche | 5 Wochen | ||||||||||
Strahlentherapie | 45 Gy in 25 Fraktionen in 5 Wochen plus Boost. | |||||||||||||
Patienten | 1608 Patienten mit Rektumkarzinom im klinischen Stadium II oder III praeoperativ | |||||||||||||
Teil von |
Rektum - Karzinom: Studien | Rektum - Karzinom | Gastro - Intestinale Tumore | |||||||||||
Quellen |
1.) Allegra CJ, et al.: J Clin Oncol 32(2014) Suppl 3, Abstr 390 2.) Russell MM, et al.: Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer: Patient-Reported Outcomes in National Surgical Adjuvant Breast and Bowel Project Randomized Trial R-04. Ann Surg. 2014 Mar 25. [Epub ahead of print] |
|||||||||||||
Impressum Zuletzt geändert am 02.09.2015 22:20